As the fear of Ebola in the US subsides as the 21-day incubation period for Ebola passes for many in Texas without new infections, this bio-tech working on a cure/vaccine for ebola should pull back. IMO, this run up has been due to fear of a major breakout in the US due to constant news coverage and is not connected to any backing fundamentals.
Technicals noted chart.
Comments
ss1
⋅
We're in news mode right now. When a story comes out it pops. When same old stories keep coming up then it wanes. Those are the kind of stories that have really effected price action. So what are the odds of another domestic case or more infected health workers being brought into the U.S. to be treated? Considering the estimates of exponential growth moving into Nov. the odds shoot higher and higher. Shorting at this level is very risky as the media seems hungry to keep this story going. It's been a good trade, but I'm advising all my shorts to take some profits off the table now before the next swing up happens.
Audacity618
⋅
It didn't seem to spike much on New York Ebola case. Is there any other type of scheduled announcements about their drug pipeline that could squeeze this? I'm still short, targeting for Gap.